Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate presentation on Tuesday, September 30, 2025, at 10:15 AM ET.
The virtual event will include a corporate presentation and one-on-one meetings with management. Investors interested in scheduling meetings can contact Lytham Partners directly or register through the conference website.
Reviva Pharmaceuticals (NASDAQ: RVPH), una società farmaceutica in fase avanzata focalizzata su malattie CNS, infiammatorie e cardiometaboliche, ha annunciato la propria partecipazione alla prossima conferenza per investitori autunnale 2025 di Lytham Partners. Il fondatore, presidente e CEO della società, Laxminarayan Bhat, Ph.D., terrà una presentazione aziendale martedì 30 settembre 2025 alle 10:15 AM ET.
L’evento virtuale includerà una presentazione aziendale e incontri one-on-one con il management. Gli investitori interessati a fissare incontri possono contattare direttamente Lytham Partners o registrarsi tramite il sito web della conferenza.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en enfermedades del SNC, inflamatorias y cardiometabólicas, anunció su participación en la próxima conferencia de inversores de otoño 2025 de Lytham Partners. El fundador, presidente y CEO de la compañía, Laxminarayan Bhat, Ph.D., ofrecerá una presentación corporativa el martes 30 de septiembre de 2025, a las 10:15 AM ET.
El evento virtual incluirá una presentación corporativa y reuniones 1 a 1 con la alta dirección. Los inversores interesados en programar reuniones pueden ponerse en contacto directamente con Lytham Partners o registrarse a través del sitio web de la conferencia.
Reviva Pharmaceuticals (NASDAQ: RVPH), CNS, 염증 및 심대사 질환에 중점을 둔 후기 단계 제약회사로, 다가오는 Lytham Partners Fall 2025 Investor Conference에 참여를 발표했습니다. 회사의 창립자이자 회장 겸 CEO인 Laxminarayan Bhat, Ph.D.가 2025년 9월 30일 화요일 동부 표준시 10:15 AM에 기업 프레젠테이션을 진행합니다.
가상 행사는 기업 프레젠테이션과 경영진과의 1:1 미팅을 포함합니다. 회의를 예약하고자 하는 투자자들은 Lytham Partners에 직접 연락하거나 컨퍼런스 웹사이트를 통해 등록할 수 있습니다.
Reviva Pharmaceuticals (NASDAQ: RVPH), une société pharmaceutique en phase avancée axée sur les maladies du SNC, inflammatoires et cardiométaboliques, a annoncé sa participation à la prochaine conférence d’investissement d’automne 2025 de Lytham Partners. Le fondateur, président et PDG de l’entreprise, Laxminarayan Bhat, Ph.D., prononcera une présentation d’entreprise le mardi 30 septembre 2025 à 10h15 AM ET.
L’événement virtuel comprendra une présentation d’entreprise et des entretiens individuels avec la direction. Les investisseurs intéressés à planifier des rendez-vous peuvent contacter directement Lytham Partners ou s’inscrire via le site web de la conférence.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein späte Phase-Pharmaunternehmen mit Fokus auf CNS-, Entzündungs- und cardiometabolische Erkrankungen, kündigte seine Teilnahme an der kommenden Lytham Partners Fall 2025 Investor Conference an. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird am Dienstag, 30. September 2025, um 10:15 Uhr ET eine Unternehmenspräsentation halten.
Die virtuelle Veranstaltung wird eine Unternehmenspräsentation und One-on-One-Gespräche mit dem Management umfassen. Investoren, die Meetings planen möchten, können sich direkt an Lytham Partners wenden oder sich über die Konferenzwebsite registrieren.
تعلن Reviva Pharmaceuticals (ناسداك: RVPH)، شركة أدوية متقدمة تركز على أمراض الجهاز العصبي المركزي والالتهابات والأمراض القلبية الأيضية، عن مشاركتها في مؤتمر المستثمرين خريف 2025 القادم من Lytham Partners. سيقدم المؤسس والرئيس التنفيذي للشركة، Laxminarayan Bhat, Ph.D.، عرضًا تنظيميًا في الثلاثاء 30 سبتمبر 2025 الساعة 10:15 صباحًا بتوقيت شرق الولايات المتحدة.
يشمل الحدث الافتراضي عرضًا تنظيميًا واجتماعات فردية مع الإدارة. يمكن للمستثمرين الراغبين في جدولة الاجتماعات التواصل مباشرة مع Lytham Partners أو التسجيل من خلال موقع المؤتمر.
Reviva Pharmaceuticals (纳斯达克：RVPH)，一家专注于中枢神经系统、炎症和心代谢疾病的后期药物公司，宣布参加即将举行的 Lytham Partners 2025 秋季投资者大会。公司创始人、总裁兼首席执行官 Laxminarayan Bhat, Ph.D. 将于 2025 年 9 月 30 日，星期二，东部时间 10:15 AM 进行企业介绍。
此次线上活动将包括企业介绍和与管理层的一对一会谈。希望安排会面的投资者可以直接联系 Lytham Partners，或通过大会网站注册。
- None.
- None.
CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.
Lytham Partners Fall 2025 Investor Conference
Format: Corporate Presentation and one-on-one meetings
Date: Tuesday, September 30, 2025
Time: 10:15 AM ET
Registration Link: Click Here
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at rvph@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the Lytham Partners Fall 2025 Conference?
How can investors attend Reviva's (RVPH) presentation at the Lytham Partners Conference?
Who will be presenting for Reviva Pharmaceuticals at the Lytham Partners Conference?
How can investors schedule one-on-one meetings with Reviva's management?
